Abstract: The invention relates to antibodies, or antigen-binding fragments thereof, that specifically binds to killer cell lectin-like receptor G1 (KLRG1). Such antibodies, or antigen-binding fragments thereof, are useful for various therapeutic or diagnostic purposes including treatment of cancers and to increase the effectiveness of vaccines.

Abstract: Described herein are novel and improved antibodies that bind Interleukin 13 (IL-13) and methods of use thereof. In certain aspects, described herein are methods of inhibiting IL-13 biological activity. In certain aspects, described herein are pharmaceutical compositions comprising the anti-IL-13 antibodies. In certain aspects, the antibodies and methods described herein are used for treatment of an inflammatory disease or disorder associated with elevated levels of IL-13 and/or IgE.

Abstract: A fog and dancing liquid lantern which includes a chamber secured between a base and a lid. The lid contains an ultrasonic mister, which is directed into the chamber to create fog effect therein. A lower surface of the chamber contains several orifices. The base contains a dancing liquid assembly, which includes an enclosure containing a motorized impeller secured adjacent to a pump chamber. A nozzle is secured adjacent to the pump chamber and includes channels that correspond with and extend into the orifices. A speaker is secured within the base and the motorized impeller is programmed to increase and decrease speed in synchronization with a sound played through the speaker, thereby producing taller and short oil columns in the chamber. The lantern is activated manually or wirelessly and produces these features independently or simultaneously.

Abstract: The receptor killer cell lectin-like receptor G1 (KLRG1) is expressed on T and NK cells, which binds to ligands on epithelial and mesenchymal cells. The ligand for KLRG1 has been described to be E-cadherin, N-cadherin, and R-cadherin. The present disclosure relates to and results from the discovery and characterization of antibodies that bind the extracellular domain (ECD) of KLRG1 but do not interfere with its interaction with the ligands E-cadherin, N-cadherin, and R-cadherin. The antibodies described have been derived by mouse hybridoma technology, and can be humanized by grafting their complementary determining regions (CDRs) into a human framework. The antibodies described can be used as effective therapeutic agents. Various antibodies, or antigen-binding fragments of such antibodies, along with various therapeutic and/or diagnostic methods, among other features, are provided for in the present disclosure.

Abstract: The invention relates to antibodies, or fragments thereof, that specifically bind to KLRG1, methods of depleting killer cell lectin-like receptor GI (KLRG1) expressing T cells and/or NK cells in a subject in need thereof of, methods of treating a disorder associated with excess KLRG1-expressing T cells in a subject in need thereof, methods of treating cancer in a subject, adjunct therapies for treatment of cancer in a subject, methods of depleting KLRG1-expressing cells in a mixed population of cells, methods of selectively depleting KLRG1-expressing CDS effector T cells, pharmaceutical compositions of anti-KLRG1 antibodies, and kits for anti-KLRG1 antibodies.

Abstract: The receptor killer cell lectin-like receptor G1 (KLRG1) is expressed on T and NK cells, which binds to ligands on epithelial and mesenchymal cells. The ligand for KLRG1 has been described to be E-cadherin, N-cadherin, and R-cadherin. The present disclosure relates to and results from the discovery and characterization of antibodies that bind the extracellular domain (ECD) of KLRG1 but do not interfere with its interaction with the ligands E-cadherin, N-cadherin, and R-cadherin. The antibodies described have been derived by mouse hybridoma technology, and can be humanized by grafting their complementary determining regions (CDRs) into a human framework. The antibodies described can be used as effective therapeutic agents. Various antibodies, or antigen-binding fragments of such antibodies, along with various therapeutic and/or diagnostic methods, among other features, are provided for in the present disclosure.

Abstract: A smart speaker power controller may be configured to receive power conforming to one of a plurality of power modes from an input power source. The power controller may be further configured to communicate the power mode to at least one component of a processing system or at least one component of an audio system for operating the smart speaker according to the received power mode, including determining a current limit of a power converter; determining a shutdown voltage threshold and safely shutting down the smart speaker if the input voltage falls below the threshold, and/or modifying audio operation of the smart speaker in response to the power mode. The smart speaker can further include an audio power supply controller configured to monitor energy required to reproduce an audio signal and to servo a power supply voltage provided to an audio amplifier in response to this energy level.

Abstract: The disclosure relates to antibodies, or antigen-binding fragments thereof, that specifically bind to killer cell lectin-like receptor G1 (KLRG1). Such antibodies, or antigen-binding fragments thereof, are useful for various therapeutic or diagnostic purposes, including treatment of cancers and to increase the effectiveness of vaccines.

Abstract: A smart speaker power controller may be configured to receive power conforming to one of a plurality of power modes from an input power source. The power controller may be further configured to communicate the power mode to at least one component of a processing system or at least one component of an audio system for operating the smart speaker according to the received power mode, including determining a current limit of a power converter; determining a shutdown voltage threshold and safely shutting down the smart speaker if the input voltage falls below the threshold, and/or modifying audio operation of the smart speaker in response to the power mode. The smart speaker can further include an audio power supply controller configured to monitor energy required to reproduce an audio signal and to servo a power supply voltage provided to an audio amplifier in response to this energy level.

Abstract: A smart speaker power controller may be configured to receive power conforming to one of a plurality of power modes from an input power source. The power controller may be further configured to communicate the power mode to at least one component of a processing system or at least one component of an audio system for operating the smart speaker according to the received power mode, including determining a current limit of a power converter; determining a shutdown voltage threshold and safely shutting down the smart speaker if the input voltage falls below the threshold, and/or modifying audio operation of the smart speaker in response to the power mode. The smart speaker can further include an audio power supply controller configured to monitor energy required to reproduce an audio signal and to servo a power supply voltage provided to an audio amplifier in response to this energy level.

Abstract: A method of treating a subject can include administering to a subject in need thereof an effective amount of a killer cell lectin-like receptor G1 (KLRG1)/ligand binding agent, thereby disrupting KLRG1 signaling and activating CD8+ cytotoxic T and/or NK cells. A method of treating cancer can include administering to a subject in need thereof an effective amount of a killer cell lectin-like receptor G1 (KLRG1)/ligand binding agent. The methods can treat various cancers, for example melanoma, lung cancer, pancreatic cancer, glioma, breast cancer, and ovarian cancer.

Abstract: The receptor killer cell lectin-like receptor G1 (KLRG1) is expressed on T and NK cells, which binds to ligands on epithelial and mesenchymal cells. The ligand for KLRG1 has been described to be E-cadherin, N-cadherin, and R-cadherin. The present disclosure relates to and results from the discovery and characterization of antibodies that bind the extracellular domain (ECD) of KLRG1 but do not interfere with its interaction with the ligands E-cadherin, N-cadherin, and R-cadherin. The antibodies described have been derived by mouse hybridoma technology, and can be humanized by grafting their complementary determining regions (CDRs) into a human framework. The antibodies described can be used as effective therapeutic agents. Various antibodies, or antigen-binding fragments of such antibodies, along with various therapeutic and/or diagnostic methods, among other features, are provided for in the present disclosure.

Abstract: A smart speaker power controller may be configured to receive power conforming to one of a plurality of power modes from an input power source. The power controller may be further configured to communicate the power mode to at least one component of a processing system or at least one component of an audio system for operating the smart speaker according to the received power mode, including determining a current limit of a power converter; determining a shutdown voltage threshold and safely shutting down the smart speaker if the input voltage falls below the threshold, and/or modifying audio operation of the smart speaker in response to the power mode. The smart speaker can further include an audio power supply controller configured to monitor energy required to reproduce an audio signal and to servo a power supply voltage provided to an audio amplifier in response to this energy level.

Abstract: The receptor killer cell lectin-like receptor G1 (KLRG1) is expressed on T and NK cells, which binds to ligands on epithelial and mesenchymal cells. The ligand for KLRG1 has been described to be E-cadherin, N-cadherin, and R-cadherin. The present disclosure relates to and results from the discovery and characterization of antibodies that bind the extracellular domain (ECD) of KLRG1 but do not interfere with its interaction with the ligands E-cadherin, N-cadherin, and R-cadherin. The antibodies described have been derived by mouse hybridoma technology, and can be humanized by grafting their complementary determining regions (CDRs) into a human framework. The antibodies described can be used as effective therapeutic agents. Various antibodies, or antigen-binding fragments of such antibodies, along with various therapeutic and/or diagnostic methods, among other features, are provided for in the present disclosure.

Abstract: The invention relates to antibodies, or antigen-binding fragments thereof, that specifically binds to killer cell lectin-like receptor G1 (KLRG1). Such antibodies, or antigen-binding fragments thereof, are useful for various therapeutic or diagnostic purposes including treatment of cancers and to increase the effectiveness of vaccines.

Abstract: A method of treating a subject can include administering to a subject in need thereof an effective amount of a killer cell lectin-like receptor G1 (KLRG1)/ligand binding agent, thereby disrupting KLRG1 signaling and activating CD8+ cytotoxic T and/or NK cells. A method of treating cancer can include administering to a subject in need thereof an effective amount of a killer cell lectin-like receptor G1 (KLRG1)/ligand binding agent. The methods can treat various cancers, for example melanoma, lung cancer, pancreatic cancer, glioma, breast cancer, and ovarian cancer.

Abstract: A motor vehicle system for generating and transmitting motor vehicle imaging object data includes a communication system module positioned in a host vehicle receiving vehicle attribute data during host vehicle highway travel and preparing a fused object attribute data for transmission. An imaging device collects object imaging data representing objects within a visible detection range of the imaging device. An object detection and classification system module has an object classification sub-module used to classify the objects within the visible detection range as a vehicle type or a pedestrian and to output each as an object attribute data. A target fusion module receives the object attribute data from the object detection and classification system module, fuses the object attribute data with the vehicle attribute data to create the fused object attribute data, and forwards the fused object attribute data to the communication system module for transmission.

Abstract: A fluid delivery system for dispensing fluid can include a dispenser, such as a trigger engine-type dispenser, configured to draw fluid up from a container. A nozzle assembly can include a nozzle, and a nozzle slide. The nozzle slide can be configured to slide and/or rotate relative to the shroud to provide different dispensing modes. In alternative examples, the nozzle can be configured to rotate in 30 degree increments relative to the shroud to provide the different dispensing modes or the nozzle assembly can include a nozzle extension, and the nozzle extension can be configured to rotate relative to the shroud to provide different dispensing patterns out of the nozzle. In another example a first nozzle can be configured to provide one or more dispensing modes, and a second nozzle can be configured to provide a different dispensing mode than the first nozzle. Methods of dispensing fluids and methods of assembling fluid dispensers are also disclosed.

Abstract: A method of treating a subject can comprise administering to a subject in need thereof an effective amount of a killer cell lectin-like receptor G1 (KLRG1) depleting agent, thereby depleting CD8+ cytotoxic T and/or NK cells in vivo. A method of treating a subject can comprise administering to a subject in need thereof an effective amount of a KLRG1 depleting agent with effector killing function. A composition, for example an anti-KLRG1 antibody, can comprise a KLRG1 depleting agent. The methods and compositions can be used for various diseases in which KLRG1 is overexpressed, for example autoimmune diseases, transplant rejection, hematologic malignancies, and solid tumors.

Abstract: A method of generating and communicating lane information from a host vehicle to a vehicle-to-vehicle (V2V) network includes collecting visual data from a camera, detecting a lane within the visual data, generating a lane classification for the lane based on the visual data, assigning a confidence level to the lane classification, generating a lane distance estimate from the visual data, generating a lane model from the lane classification and the lane distance estimate, and transmitting the lane model and the confidence level to the V2V network.